CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Astrazeneca PLC (AZN) / camizestrant
Forward catalyst · AZN

camizestrant

Sponsor Astrazeneca PLC · listed as AZN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

camizestrant is a clinical-stage drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Aug 24, 2026 (day precision, medium confidence), tied to trial NCT04711252. The asset is in Phase 3 and currently active not recruiting, studied in ER-Positive HER2-Negative Breast Cancer. It appears across 6 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-08-24
As disclosedAug 24, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT04711252
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorAstraZeneca
Listed asAZN
Condition(s)ER-Positive HER2-Negative Breast Cancer

All tracked catalysts for camizestrant

DateEventConfidenceTrial
2026-08-24READOUTmediumNCT04711252
2027-04-20READOUTmediumNCT05774951
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More AZN catalysts